Many clinical and preclinical studies are currently investigating the importance of targeting PI3K in HER2-positive breast cancer, however the MEK/MAPK pathway has also been recently established as a potential target for therapy in oncology patients [12]. This evidence concerns the gene MAP2K7 and breast carcinoma.